Cantor Fitzgerald Comments on DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings of ($0.62) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Bright Minds Biosciences' current full-year earnings is ($2.58) per share.

A number of other equities research analysts also recently commented on the stock. HC Wainwright started coverage on shares of Bright Minds Biosciences in a report on Friday, January 10th. They set a "buy" rating and a $85.00 price target for the company. Piper Sandler began coverage on shares of Bright Minds Biosciences in a research note on Thursday. They issued an "overweight" rating and a $93.00 target price for the company. Robert W. Baird started coverage on Bright Minds Biosciences in a research note on Monday, November 25th. They set an "outperform" rating and a $75.00 price target on the stock. Finally, Baird R W raised Bright Minds Biosciences to a "strong-buy" rating in a research report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bright Minds Biosciences has a consensus rating of "Buy" and an average price target of $84.33.

Bright Minds Biosciences Price Performance

DRUG stock traded down $1.07 during trading on Thursday, hitting $32.28. The stock had a trading volume of 366,519 shares, compared to its average volume of 103,808. The stock has a market cap of $143.00 million, a price-to-earnings ratio of -64.56 and a beta of -6.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.31 and a current ratio of 11.31. The company's 50 day moving average price is $38.57 and its two-hundred day moving average price is $21.00. Bright Minds Biosciences has a 1-year low of $0.93 and a 1-year high of $79.02.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last released its quarterly earnings results on Monday, December 30th. The company reported ($0.12) earnings per share for the quarter.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.